BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Bio-Bridge Science, Inc. Signs an Equity Sale and Purchase Agreement with Xinheng Baide Biotechnology Co. Ltd.


5/1/2008 8:41:10 AM

OAK BROOK, Ill.--(BUSINESS WIRE)--Bio-Bridge Science, Inc. (OTCBB:BGES), a biotechnology company engaged in the commercial development of vaccines for the prevention and treatment of human infectious diseases announced today that its wholly-owned subsidiary, Bio-Bridge Science (HK) Co., Ltd. has entered into a sale and purchase agreement (the "Agreement") with Xinheng Baide Biotechnology Co. Ltd. (the “Seller” or “Xinheng Baide”), a serum manufacturing company organized under the laws of the PRC, pursuant to which BGES has agreed to purchase newly issued shares of Seller. After the equity issuance, BGES shall control 51% of the outstanding capital stock of the Seller for a total cash purchase price of RMB 6 million (approximately US$ 865,000). The source of the cash to be used for subscribing to the new shares issued by the Seller will be from working capital of BGES. Xinheng Baide, located in the city of Huhhot in Inner Mongolia of the People’s Republic of China, manufactures and distributes bovine serum and other related products primarily in China. Bovine serum is used in vaccine production as well as scientific research. The sale and purchase agreement and related documents are subject to Chinese governmental approval. BGES expects to close the deal at the end of May 2008.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES